None
Quote | Oncternal Therapeutics Inc. (NYSE:ONCT)
Last: | $ |
---|---|
Change Percent: | 1.28% |
Open: | $3.87 |
Close: | $3.95 |
High: | $3.95 |
Low: | $3.87 |
Volume: | 7,823 |
Last Trade Date Time: | 02/12/2020 04:42:01 pm |
News | Oncternal Therapeutics Inc. (NYSE:ONCT)
2024-06-26 15:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phas...
Message Board Posts | Oncternal Therapeutics Inc. (NYSE:ONCT)
Subject | By | Source | When |
---|---|---|---|
I think that $ONCT has huge potential, but | Tartiaboy | investorshub | 03/31/2023 5:25:45 PM |
znewcar1: $ONCT 24% v528K c.8778 f58,711M H.878 ML.5951 | znewcar1 | investorshangout | 03/23/2023 9:00:25 PM |
Tartia or Decaf, Time to buy more, or sell?tia | spiderman3600 | investorshub | 03/10/2023 4:33:35 PM |
https://stocktwits.com/Stockholm111/message/509113960 | spiderman3600 | investorshub | 01/30/2023 9:48:44 PM |
I am anxiously waiting for $ONCT to initiate | Tartiaboy | investorshub | 01/27/2023 5:32:44 PM |
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NYSE Market:
Oncternal Therapeutics Inc. Website:
2024-06-26 15:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phas...
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the ...